Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Endometrial Neoplasms 7Ovarian Neoplasms 6Neoplasms 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Neuroendocrine 2Vulvar Neoplasms 1Vaginal Neoplasms 1Turcot syndrome 1Small Cell Lung Carcinoma 1Sarcoma, Clear Cell 1Sarcoma 1Recurrence 1Penile Neoplasms 1Pathologic Complete Response 1Neoplasms, Second Primary 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1MMRd/MSI-H Stage II-III Endometrial Cancer 1

Interventions

Oxaliplatin 2sintilimab 1irinotecan sucrosofate 1dostarlimab 1XELOX 1Neoadjuvant Therapy 1Immune Checkpoint Inhibitors 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Locally Advanced Rectal Cancer (LARC) × dostarlimab × Clear all
NCT07381777 2026-02-02

IMMUNOSTAR

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 2 Not yet recruiting
270 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer (LARC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡